Novo Nordisk and the diabetes epidemic

Sep 14, 2014 : Rising insulin sales have made Novo Nordisk one of the strongest growth stories in the pharma sector. FT pharmaceuticals correspondent Andrew Ward asks chief executive Lars Sørensen if the company prefers treating the disease rather than finding a cure.
1 - 12 VIEW FROM THE TOP (100)